Xiaoling Wei

Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: Primary Endpoint Analysis from the SUNSHINE and SUNRISE Phase III Trials

A. Gottlieb, L. Uhlmann, G. Jemec, 2022, EMJ Dermatology.

Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger

L. Goffin, R. Laxer, B. Lauwerys, 2019, Arthritis & rheumatology.

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

A. Gottlieb, L. Uhlmann, A. Kimball, 2023, The Lancet.

Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study

C. Wouters, N. Wulffraat, E. Alexeeva, 2020, Arthritis & rheumatology.

Canakinumab provides rapid and sustained long-term efficacy and safety in patients with cryopyrin-associated periodic syndrome aged ≤5 years.

L. Goffin, R. Laxer, B. Lauwerys, 2019, Arthritis & rheumatology.

OP0055 EFFICACY OF CANAKINUMAB, ON A REDUCED DOSE OR A PROLONGED DOSE INTERVAL WITHOUT CONCOMITANT CORTICOSTEROIDS AND METHOTREXATE, IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

C. Wouters, N. Wulffraat, E. Alexeeva, 2019, Oral Presentations.